Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Revolution Medicines Reiterates Projected Full Year 2024 GAAP Net Loss To Be $(480)M-$(520)M

Author: Benzinga Newsdesk | May 08, 2024 05:02pm

Based on the company's current operating plan, the company projects current cash, cash equivalents and marketable securities can fund planned operations into 2027.

Posted In: RVMD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist